SCHEMBL30296497

SCHEMBL30296497

Nc1cc(Cl)c(-c2ccc(OC3COC3)nc2)cc1F

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDO2 P48775 3/20 0.38
PRKAG1 P54619 2/20 0.38
PRKAA1 Q13131 2/20 0.38
PRKAB1 Q9Y478 2/20 0.38
PRKAB2 O43741 1/20 0.38
PRKAA2 P54646 1/20 0.38
PRKAG3 Q9UGI9 1/20 0.38
PRKAG2 Q9UGJ0 1/20 0.38
PAICS P22234 2/20 0.36
KMO O15229 2/20 0.36
FAAH O00519 2/20 0.36
STIM1 Q13586 2/20 0.35
ORAI1 Q96D31 2/20 0.35
EGFR P00533 2/20 0.34
ITK Q08881 2/20 0.34
ALOX5AP P20292 1/20 0.34
FEN1 P39748 1/20 0.34
KCNH2 Q12809 1/20 0.33
DGAT1 O75907 1/20 0.33
FFAR4 Q5NUL3 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26459487 1.00 TDO2 (0.38) TDO2PRKAG1PRKAA1PRKAB1PRKAB2
SCHEMBL30296443 0.91 EGFR (0.42) TDO2PRKAG1PRKAA1PRKAB1PRKAB2
SCHEMBL26461339 0.91 EGFR (0.42) TDO2PRKAG1PRKAA1PRKAB1PRKAB2
SCHEMBL30296663 0.89 TDO2 (0.45) TDO2PRKAG1PRKAA1PRKAB1PAICS
SCHEMBL31207378 0.89 ALOX5AP (0.45) TDO2PAICSEGFRITKALOX5AP
SCHEMBL30296462 0.87 TDO2 (0.43) TDO2PAICSFAAHEGFRITK
SCHEMBL26461154 0.87 TDO2 (0.43) TDO2PAICSFAAHEGFRITK
SCHEMBL30296607 0.87 TDO2 (0.43) TDO2PAICSFAAHEGFRITK
SCHEMBL30296242 0.86 TDO2 (0.38) TDO2PRKAG1PRKAA1PRKAB1PAICS
SCHEMBL26459805 0.86 TDO2 (0.38) TDO2PRKAG1PRKAA1PRKAB1PAICS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240368173-A1 TRICYCLIC GPR65 MODULATORS Pathios Therapeutics Limited (GB) 2024-11-07 US disclosed
EP-4419203-A1 TRICYCLIC GPR65 MODULATORS Pathios Therapeutics Limited (GB) 2024-08-28 EP disclosed
CN-118451080-A Tricyclic GPR65 modulators 帕蒂奥斯治疗有限公司 2024-08-06 CN disclosed
WO-2023067322-A1 TRICYCLIC GPR65 MODULATORS Pathios Therapeutics Limited (GB) 2023-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240368173-A1 TRICYCLIC GPR65 MODULATORS GPR65, GPR3, NR1H2 TDO2 2047/4885PRKAG1 1606/4885PRKAA1 2106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.